Effect of a program to reduce hospital ciprofloxacin use on nosocomial Pseudomonas aeruginosa susceptibility to quinolones and other antimicrobial agents

Infection Control and Hospital Epidemiology

Volumn 29, Issue 8, 2008, Pages 716-722

  Cook, Paul P ^a   Das, Titu D ^a   Gooch, Michael ^b   Catrou, Paul G ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

^b University Health Systems of Eastern Carolina   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFEPIME; CIPROFLOXACIN; IMIPENEM; MEROPENEM; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; HEALTH PROGRAM; HOSPITAL INFECTION; HUMAN; INCIDENCE; PREVALENCE; PSEUDOMONAS AERUGINOSA;

ANTI-INFECTIVE AGENTS; CIPROFLOXACIN; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; HOSPITAL BED CAPACITY, 500 AND OVER; HOSPITALS, TEACHING; HUMANS; INCIDENCE; MICROBIAL SENSITIVITY TESTS; PROGRAM EVALUATION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; QUINOLONES;

EID: 50949119494     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/589813     Document Type: Article

References (29)

1. Richards MJ, Edwards JR, Culver DH, et al. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 1999;27:887-892.
2. Burwen DR, Banerjee SN, Gaynes RP. Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States. J Infect Dis 1994;170:1622-1625.
3. Quinn JP, Dudek EJ, DiVincenzo CA, et al. Emergence of resistance to imipenem during therapy for Pseudomonas aeruginosa infections. J Infect Dis 1986;154:289-294.
4. Neuhauser MM, Weinstein RA, Rydman R, et al. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003;289:885-888.
5. John JF Jr, Fishman NO. Programmatic role of the infectious disease physician in controlling antimicrobial cost in the hospital. Clin Infect Dis 1997;24:471-485.
6. Shlaes DM, Gerding DN, John JF, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance guidelines for the prevention of antimicrobial resistance in hospitals. Infect Control Hosp Epidemiol 1997;18:275-291.
7. Rahal JJ, Urban C, Horn D, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998;280:1233-1237.
8. Cook PP, Catrou PG, Christie JD, et al. Reduction in broad-spectrum antimicrobial use associated with no improvement in hospital antibiogram. J Antimicrob Chemother 2004;53:853-859.
9. World Health Organization Collaborating Centre for Drug Statistics Methodology Web site. Available at: http://www.whocc.no/atcddd/. Accessed January 22, 2008.
10. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39:309-317.
11. El Amari EB, Chamot E, Auckenthaler R, Pechere JC, Van Delden C. Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. Clin Infect Dis 2001;33:1859-1864.
12. Levin PD, Fowler RA, Guest C, et al. Risk factors associated with resistance to ciprofloxacin in clinical isolates from intensive care unit patients. Infect Control Hosp Epidemiol 2007;28:331-336.
13. Patterson JE, Hardin TC, Kelly CA, et al. Association of antibiotic utilization measures and control of multiple-drug resistance in Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2000;21:455-458.
14. Ntagiopoulos PG, Paramythiotou E, Antoniadou A, et al. Impact of an antibiotic restriction policy on the antibiotic resistance patterns of gram-negative microorganisms in an intensive care unit in Greece. Int J Antimicrob Agents 2007;30:360-365.
15. Aubert G, Carricajo A, Vautrin AC, et al. Impact of restricting fluoroquinolone prescription on bacterial resistance in an intensive care unit. J Hosp Infect 2005;59:83-89.
16. Burke JP. Antibiotic resistance - squeezing the balloon? JAMA 1998;280:1270-1271.
17. MacDougall C, Harpe SE, Powell JP, et al. Pseudomonas aeruginosa, Staphylococcus aureus, and fluoroquinolone use. Emerg Infect Dis 2005;11:1197-1204.
18. Rogues AM, Dumartin C, Amadéo B, et al. Relationship between rates of antimicrobial consumption and the incidence of antimicrobial resistance in Staphylococcus aureus and Pseudomonas aeruginosa isolates from 47 French hospitals. Infect Control Hosp Epidemiol 2007;28:1389-1395.
19. Schwaber MJ, De-Medina T, Carmeli Y. Epidemiological interpretation of antibiotic resistance studies - what are we missing? Nat Rev Microbiol 2004;2:979-983.
20. Monnet DL, MacKenzie FJ, López-Lozano JM, et al. Antimicrobial drug use and methicillin-resistant Staphylococcus aureus, Aberdeen, 1996-2000. Emerg Infect Dis 2004;10:1432-1441.
21. Polk RE, Johnson CK, McClish D, Wenzel RP, Edmond MB. Predicting hospital rates of fluoroquinolone-resistant Pseudomonas aeruginosa from fluoroquinolone use in US hospitals and their surrounding communities. Clin Infect Dis 2004;39:497-450.
22. Paramythiotou E, Lucet JC, Timsit JF, et al. Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clin Infect Dis 2004;38:670-677.
23. Weber SG, Gold HS, Hooper DC, Karchmer AW, Carmeli Y. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis 2003;9:1415-1422.
24. MacDougall C, Powell JP, Johnson CK, Edmond MB, Polk RE. Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals. Clin Infect Dis 2005;41:435-440.
25. Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005;41:1254-1260.
26. Muto CA, Pokrywka M, Shutt K, et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005;26:273-280.
27. McCusker ME, Harris AD, Perencevich E, Roghmann MC. Fluoroquinolone use and Clostridium difficile-associated diarrhea. Emerg Infect Dis 2003;9:730-733.
28. Cook PP, Catrou P, Gooch M, Holbert D. Effect of reduction in ciprofloxacin use on prevalence of methicillin-resistant Staphylococcus aureus rates within individual units of a tertiary care hospital. J Hosp Infect 2006;64:348-351.
29. Valiquette L, Cossette B, Garant MP, Diab H, Pepin J. Impact of a reduction in the use of high risk antibiotics on the course of an epidemic of Clostridium difficile-associated disease caused by the hypervirulent NAP1/027 strain. Clin Infect Dis 2007;45(suppl 2):S112-S121.